| HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells MR Betts, MC Nason, SM West, SC De Rosa, SA Migueles, J Abraham, ... Blood 107 (12), 4781-4789, 2006 | 2258 | 2006 |
| Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 X Wu, ZY Yang, Y Li, CM Hogerkorp, WR Schief, MS Seaman, T Zhou, ... Science 329 (5993), 856-861, 2010 | 2016 | 2010 |
| SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness KS Corbett, DK Edwards, SR Leist, OM Abiona, S Boyoglu-Barnum, ... Nature 586 (7830), 567-571, 2020 | 1422 | 2020 |
| Plasma levels of soluble CD14 independently predict mortality in HIV infection NG Sandler, H Wand, A Roque, M Law, MC Nason, DE Nixon, ... Journal of Infectious Diseases 203 (6), 780-790, 2011 | 1259 | 2011 |
| Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates KS Corbett, B Flynn, KE Foulds, JR Francica, S Boyoglu-Barnum, ... New England Journal of Medicine 383 (16), 1544-1555, 2020 | 1140 | 2020 |
| Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine RA Seder, LJ Chang, ME Enama, KL Zephir, UN Sarwar, IJ Gordon, ... Science 341 (6152), 1359-1365, 2013 | 908 | 2013 |
| Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial PB Gilbert, DC Montefiori, AB McDermott, Y Fong, D Benkeser, W Deng, ... Science 375 (6576), 43-50, 2022 | 899 | 2022 |
| SPICE: exploration and analysis of post‐cytometric complex multivariate datasets M Roederer, JL Nozzi, MC Nason Cytometry Part A 79 (2), 167-174, 2011 | 876 | 2011 |
| Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine AR Falsey, ME Sobieszczyk, I Hirsch, S Sproule, ML Robb, L Corey, ... New England Journal of Medicine 385 (25), 2348-2360, 2021 | 582 | 2021 |
| Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants A Pegu, SE O’Connell, SD Schmidt, S O’Dell, CA Talana, L Lai, J Albert, ... Science 373 (6561), 1372-1377, 2021 | 516 | 2021 |
| Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression NG Sandler, SE Bosinger, JD Estes, RTR Zhu, GK Tharp, E Boritz, ... Nature 511 (7511), 601-605, 2014 | 492 | 2014 |
| Rapid development of a DNA vaccine for Zika virus KA Dowd, SY Ko, KM Morabito, ES Yang, RS Pelc, CR DeMaso, ... Science 354 (6309), 237-240, 2016 | 414 | 2016 |
| Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies NA Doria-Rose, RM Klein, MM Manion, S O'Dell, A Phogat, B Chakrabarti, ... Journal of virology 83 (1), 188-199, 2009 | 412 | 2009 |
| Perforin Expression Directly Ex Vivo by HIV-Specific CD8+ T-Cells Is a Correlate of HIV Elite Control AR Hersperger, F Pereyra, M Nason, K Demers, P Sheth, LY Shin, ... PLoS pathogens 6 (5), e1000917, 2010 | 406 | 2010 |
| Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables NA Doria-Rose, RM Klein, MG Daniels, S O'Dell, M Nason, A Lapedes, ... Journal of virology 84 (3), 1631-1636, 2010 | 391 | 2010 |
| Protection against malaria at 1 year and immune correlates following PfSPZ vaccination AS Ishizuka, KE Lyke, A DeZure, AA Berry, TL Richie, FH Mendoza, ... Nature medicine 22 (6), 614-623, 2016 | 368 | 2016 |
| Enhanced neonatal Fc receptor function improves protection against primate SHIV infection SY Ko, A Pegu, RS Rudicell, Z Yang, MG Joyce, X Chen, K Wang, S Bao, ... Nature 514 (7524), 642-645, 2014 | 366 | 2014 |
| Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera JO Ngwuta, M Chen, K Modjarrad, MG Joyce, M Kanekiyo, A Kumar, ... Science translational medicine 7 (309), 309ra162-309ra162, 2015 | 363 | 2015 |
| A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges R Gautam, Y Nishimura, A Pegu, MC Nason, F Klein, A Gazumyan, ... Nature 533 (7601), 105-109, 2016 | 350 | 2016 |
| Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques M Shingai, OK Donau, RJ Plishka, A Buckler-White, JR Mascola, ... Journal of Experimental Medicine 211 (10), 2061-2074, 2014 | 350 | 2014 |
John mascolaNational Institutes of HealthVerified email at mail.nih.gov
